Precigen (PGEN) has moved into the commercial spotlight after PAPZIMEOS received FDA approval for recurrent respiratory papillomatosis, with US sales underway and a new CMS J-code, J3404, effective April 1, 2026.
See our latest analysis for Precigen.
At a share price of US$4.17, Precigen has seen an 18.8% 1 month share price return while its 1 year total shareholder return is very large, which suggests recent PAPZIMEOS news is feeding into stronger sentiment and shifting risk perceptions around the business.
If PAPZIMEOS has put Precigen on your radar, it could be worth widening your search to other high potential biotech names by checking out 34 healthcare AI stocks
With Precigen now generating PAPZIMEOS sales, a 1 year total shareholder return that is very large, and a recent share price of US$4.17 versus a US$9.50 analyst target, the question is whether this represents an undervalued biotech or a market already pricing in future growth.
Most Popular Narrative: 50.9% Undervalued
Precigen's most followed valuation story pegs fair value at $8.50 per share, compared with the last close at $4.17, framing a sizeable upside gap in that narrative.
Expanding indications, including the planned pediatric RRP trial and geographic expansion via the EMA marketing authorization application, create additional addressable markets that can extend the revenue growth curve and leverage existing commercial infrastructure.
Want to see what sits behind that ambitious view on future markets and margins? The narrative leans on rapid revenue expansion, rising profitability, and a richer earnings multiple to support that $8.50 fair value.
Result: Fair Value of $8.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story depends on PAPZIMEOS sustaining its current momentum and on financing staying manageable, since slower uptake or fresh capital needs could quickly cool the bullish narrative.
Find out about the key risks to this Precigen narrative.
Another View: Rich P/B Raises Questions
While the narrative points to undervaluation, the P/B ratio tells a very different story. Precigen trades at 70.6x book value, compared with 2.3x for the US Biotechs industry and 14.9x for peers. This suggests investors are paying a steep premium. Is that premium really justified by future expectations?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of optimism and concern in this story is clear, so do not wait around. Check the full balance of 2 key rewards and 3 important warning signs
Looking for more investment ideas?
If Precigen has sharpened your focus, do not stop here. Use data driven shortlists to spot other opportunities that could suit your goals before others act.
- Pinpoint potential value opportunities by checking companies highlighted in 55 high quality undervalued stocks.
- Prioritise resilience with stocks identified in the 73 resilient stocks with low risk scores.
- Hunt for under the radar opportunities using the screener containing 23 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
All Comments